Hematopoietic stem cells in combinatorial therapy with immune checkpoint inhibitors against cancer
AssigneeUniversity of Florida Research Foundation, Inc.
InventorsDuane Mitchell, Catherine Flores
Life of this patent
Estimating the term…
Abstract
The novel synergistic combination of immune checkpoint blockade and hematopoietic stem cell transplantation and/or hematopoietic stem cell mobilization yield synergistic effects in disease therapy.
Claims24
A method for treating a cancer comprising administering to a subject having the cancer one or more immune checkpoint inhibitors, and administering to the subject hematopoietic stem cells, in amounts effective to treat the cancer, wherein the one or more immune checkpoint inhibitors are each an antagonist of lymphocyte activation gene 3 (LAG3), B and T lymphocyte attenuator (BTLA), and/or T cell membrane protein 3 (TIM3), and wherein the source of hematopoietic stem cells is autologous or wherein the source of hematopoietic stem cells is allogenic and the donor cells are HLA-matched to the recipient.
A method for treating a cancer comprising administering to a subject having the cancer one or more immune checkpoint inhibitors, and administering a hematopoietic stem cell mobilizing agent, in amounts effective to treat the cancer, wherein the one or more immune checkpoint inhibitors are each an antagonist of lymphocyte activation gene 3 (LAG3), B and T lymphocyte attenuator (BTLA), and/or T cell membrane protein 3 (TIM3).
A method for treating a cancer in a subject receiving immune checkpoint inhibitor therapy for the cancer, comprising administering to the subject hematopoietic stem cells in an amount which, in combination with the immune checkpoint inhibitor therapy, is effective to treat the cancer, wherein the one or more immune checkpoint inhibitors are each an antagonist of lymphocyte activation gene 3 (LAG3), B and T lymphocyte attenuator (BTLA), and/or T cell membrane protein 3 (TIM3).
A method for treating a cancer in a subject receiving hematopoietic stem cell transplantation therapy for the cancer, comprising administering to the subject one or more immune checkpoint inhibitors in an amount which, in combination with the hematopoietic stem cell transplantation therapy, is effective to treat the cancer, wherein the one or more immune checkpoint inhibitors are each an antagonist of lymphocyte activation gene 3 (LAG3), B and T lymphocyte attenuator (BTLA), and/or T cell membrane protein 3 (TIM3).
A method of treating a subject comprising, administering a stem cell mobilizing agent to the subject, harvesting hematopoietic stem cells from the subject, enriching the harvested stem cells for CCR2 positive (CCR2+), CD34 positive (CD34+), or lineage negative (lin−) cells, administering to the subject the enriched harvested stem cells, and administering to the subject an immune checkpoint inhibitor, wherein the one or more immune checkpoint inhibitors are each an antagonist of lymphocyte activation gene 3 (LAG3), B and T lymphocyte attenuator (BTLA), and/or T cell membrane protein 3 (TIM3).
Dependencies are inferred from the claim text.